8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 4, 2010 (January 29, 2010)

Bohai Pharmaceuticals Group, Inc.

(Exact name of registrant as specified in its charter)

Nevada	000-53401	98-0588402
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

c/o Yantai Bohai Pharmaceuticals Group Co. Ltd.

No. 9 Daxin Road, Zhifu District

Yantai, Shandong Province, China 264000

(Address of principal executive offices)

Registrant’s telephone number, including area code:  +86(535)-685-7928

Link Resources, Inc.

392 Acadia Drive S.E.

Calgary, Alberta, Canada T2J 0A8

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01  Entry into a Material Definitive Agreement

Item 5.03  Amendments to Articles of Incorporation or Bylaws

On January 29, 2010, Link Resources, Inc., a Nevada corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which the Company merged with its newly formed, wholly owned subsidiary Bohai Pharmaceuticals Group, Inc., a Nevada corporation (“Merger Sub” and such merger transaction, the “Merger”).  Upon the consummation of the Merger, the separate existence of Merger Sub ceased and shareholders of the Company became shareholders of the surviving company named Bohai Pharmaceuticals Group, Inc.

As permitted by Chapter 92A.180 of Nevada Revised Statutes, the sole purpose of the Merger was to effect a change of the Company’s name.  Upon the filing of Articles of Merger (the “Articles of Merger”) with the Secretary of State of Nevada on January 29, 2010 to effect the Merger, the Company’s articles of incorporation were deemed amended to reflect the change in the Company’s corporate name.

A copy of the Articles of Merger and Agreement and Plan of Merger as filed with the Secretary of State of Nevada on January 29, 2010 and the Company’s press release announcing the Merger and the change of the Company’s name are attached as Exhibits 3.1 and 99.1, respectively.

Item 4.01  Changes In Registrant’s Certifying Accountant

(a)           Effective January 29, 2010, upon the approval of the board of directors of the Company, the Company dismissed John Kinross-Kennedy as the Company’s independent registered public accountant.

During the fiscal years ended May 31, 2009 and 2008,John Kinross-Kennedy’s reports on the financial statements of the Company contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principle.

During the fiscal years ended May 31, 2009 and 2008 and subsequent period through January 29, 2010, there have been no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K) between the Company and John Kinross-Kennedy on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of John Kinross-Kennedy, would have caused him to make reference thereto in his report on financial statements for such years.

During the fiscal years ended May 31, 2009 and 2008 and subsequent period through January 29, 2010, there were no reportable events as defined in Regulation S-K Item 304(a)(1)(v).

On January 29, 2010, the Company provided John Kinross-Kennedy with a copy of the foregoing disclosures it is making in response to Item 4.01 on this Form 8-K, and requested John Kinross-Kennedy to furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statements. A copy of John Kinross-Kennedy’s response letter, dated February 4, 2010, is attached as Exhibit 16.1 to this Form 8-K.

(b)           On January 29, 2010, upon the approval of the board of directors of the Company, Parker Randall CF (H.K.) CPA Limited (“Parker Randall”) was appointed as the independent registered public accounting firm for the Company.  During the Company’s fiscal years ended May 31, 2009 and 2008 and subsequent period through January 29,2010, the Company did not consult with Parker Randall regarding any of the matters or events set forth in Item 304(a)(2)(i) and Item 304(a)(2)(ii) of Regulation S-K. As previously reported, the Company’s fiscal year has been changed to end on June 30.

1

Item 9.01  Financial Statements and Exhibits

(c)  Exhibits.

3.1  Articles of Merger and Agreement and Plan of Merger as filed with the Secretary of State of Nevada on January 29, 2010.

16.1  Letter regarding changing of certifying accountant dated February 4, 2010.

99.1  Press Release, dated February 1, 2010, announcing the change of the Company’s name.

This Current Report on Form 8-K may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company’s plans, objectives, expectations and intentions; and (ii) other statements identified by words such as “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

February 4, 2010	LINK RESOURCES, INC.
	By:	/s/ Hongwei Qu
		Name:	Hongwei Qu
		Title:	President, Chief Executive Officer, Interim Chief Financial Officer, Treasurer and Secretary

EX-3.1

Exhibit 3.1

AGREEMENT AND PLAN OF MERGER

THIS AGREEMENT dated as of January 29, 2010.

BETWEEN:

                          Link Resources, Inc., a Nevada corporation (“Link”)

AND:

                          Bohai Pharmaceuticals Group, Inc., a Nevada corporation (“Bohai Sub”)

WHEREAS:

A.                      Bohai Sub is the wholly-owned subsidiary of Link;

B.                      The boards of directors of Bohai Sub and Link deem it advisable and in the best interests of their respective companies and shareholders that Bohai Sub be merged with and into Link, with Link remaining as the surviving corporation under the name “Bohai Pharmaceuticals Group, Inc.”;

C.                      The board of directors of Bohai Sub has approved the plan of merger embodied in this Agreement; and

D.                      The board of directors of Link has approved the plan of merger embodied in this Agreement.

THEREFORE, in consideration of the mutual agreements and covenants set forth herein, the parties hereto do hereby agree to merge on the terms and conditions herein provided, as follows:

1. THE MERGER

1.1 The Merger

Upon the terms and subject to the conditions hereof, on the Effective Date (as hereinafter defined), Bohai Sub shall be merged with and into Link in accordance with the applicable laws of the State of Nevada (the “Merger”).  The separate existence of Bohai Sub shall cease, and Link shall be the surviving corporation under the name “Bohai Pharmaceuticals Group, Inc.” (the “Surviving Corporation”) and shall be governed by the laws of the State of Nevada.

1.2 Effective Date

The Merger shall become effective on the date and at the time (the “Effective Date”) that:

(a)           the Articles of Merger, in substantially the form previously circulated among the Board of Directors, that the parties hereto intend to deliver to the Secretary of State of the State of Nevada, are accepted and declared effective by the Secretary of State of the State of Nevada;

(b)           after satisfaction of the requirements of the laws of the State of Nevada.

1.3 Articles of Incorporation

On the Effective Date, the Articles of Incorporation of Link, as in effect immediately prior to the Effective Date, shall continue in full force and effect as the Articles of Incorporation of the Surviving Corporation except that Article 1 of the Articles of Incorporation of Link, as the Surviving Corporation, shall be amended to state that the name of the corporation is “Bohai Pharmaceuticals Group, Inc.”.

1.4 Bylaws

On the Effective Date, the Bylaws of Link, as in effect immediately prior to the Effective Date, shall continue in full force and effect as the bylaws of the Surviving Corporation.

1.5 Directors and Officers

The directors and officers of Link immediately prior to the Effective Date shall be the directors and officers of the Surviving Corporation, until their successors shall have been duly elected and qualified or until otherwise provided by law, the Articles of Incorporation of the Surviving Corporation or the Bylaws of the Surviving Corporation.

2. CONVERSION OF SHARES

2.1 Common Stock of Link

Upon the Effective Date, by virtue of the Merger and without any action on the part of any holder thereof, each share of common stock of Link, par value of $0.001 per share, issued and outstanding immediately prior to the Effective Date shall be changed and converted into one fully paid and non-assessable share of the common stock of the Surviving Corporation, par value of $0.001 per share (the “Survivor Stock”).

2.2 Common Stock of Bohai Sub

Upon the Effective Date, by virtue of the Merger and without any action on the part of the holder thereof, each share of common stock of Bohai Sub, par value of $0.001 per share, issued and outstanding immediately prior to the Effective Date shall be cancelled.

2.3 Exchange of Certificates

Each person who becomes entitled to receive any Survivor Stock by virtue of the Merger shall be entitled to receive from the Surviving Corporation a certificate or certificates representing the number of Survivor Stock to which such person is entitled as provided herein.

3. EFFECT OF THE MERGER

3.1 Rights, Privileges, etc.

On the Effective Date of the Merger, the Surviving Corporation, without further act, deed or other transfer, shall retain or succeed to, as the case may be, and possess and be vested with all the rights, privileges, immunities, powers, franchises and authority, of a public as well as of a private nature, of Bohai Sub and Link; all property of every description and every interest therein, and all debts and other obligations of or belonging to or due to each of Bohai Sub and Link on whatever account shall thereafter be taken and deemed to be held by or transferred to, as the case may be, or invested in the Surviving Corporation without further act or deed, title to any real estate, or any interest therein vested in Bohai Sub or Link, shall not revert or in any way be impaired by reason of this merger; and all of the rights of creditors of Bohai Sub and Link shall be preserved unimpaired, and all liens upon the property of Bohai Sub or Link shall be preserved unimpaired, and all debts, liabilities, obligations and duties of the respective corporations shall thenceforth remain with or be attached to, as the case may be, the Surviving Corporation and may be enforced against it to the same extent as if all of said debts, liabilities, obligations and duties had been incurred or contracted by it.

3.2 Further Assurances

From time to time, as and when required by the Surviving Corporation or by its successors and assigns, there shall be executed and delivered on behalf of Bohai Sub such deeds and other instruments, and there shall be taken or caused to be taken by it such further other action, as shall be appropriate or necessary in order to vest or perfect in or to confirm of record or otherwise in the Surviving Corporation the title to and possession of all the property, interest, assets, rights, privileges, immunities, powers, franchises and authority of Bohai Sub and otherwise to carry out the purposes of this Agreement, and the officers and directors of the Surviving Corporation are fully authorized in the name and on behalf of Bohai Sub or otherwise to take any and all such action and to execute and deliver any and all such deeds and other instruments.

4. GENERAL

4.1 Abandonment

Notwithstanding any approval of the Merger or this Agreement by the shareholders of Bohai Sub or Link or both, this Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time, by mutual written agreement of Bohai Sub or Link.

4.2 Amendment

At any time prior to the Effective Date, this Agreement may be amended or modified in writing by the board of directors of both Bohai Sub and Link.

4.3 Governing Law

This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Nevada.

4.4 Counterparts

In order to facilitate the filing and recording of this Agreement, the same may be executed in any number of counterparts, each of which shall be deemed to be an original.

4.5 Electronic Means

Delivery of an executed copy of this Agreement by electronic facsimile transmission or other means of electronic communication capable of producing a printed copy will be deemed to be execution and delivery of this Agreement as of the date hereof.

IN WITNESS WHEREOF, the parties hereto have entered into and signed this Agreement as of the date set forth above.

BOHAI PHARMACEUTICALS GROUP, INC.
By:	/s/ Hongwei Qu
	Hongwei QU
	President and Chief Executive Officer
LINK RESOURCES, INC.
By:	/s/ Hongwei Qu
	Hongwei QU
	President and Chief Executive Officer

EX-99.1

Exhibit 99.1

Link Resources Announces Corporate Name Change to

Bohai Pharmaceuticals Group, Inc.

Company Working to Change Stock Symbol

FOR IMMEDIATE RELEASE — YANTAI, CHINA – February 1, 2010 - Link Resources, Inc. (OTCBB: LNKR) today announced that the company has changed its corporate name to Bohai Pharmaceuticals Group, Inc. (“Bohai”).

The name change, which was undertaken via a short form merger which occurred on January 29, 2010 between the company and a newly formed, wholly-owned Nevada subsidiary of the company, will be effective immediately.

This action follows the January 5, 2010 completion of the company’s share exchange transaction and concurrent US$12 million private placement pursuant to which the company acquired the parent company of Yantai Bohai Pharmaceuticals Group Co., Ltd.  Based in Yantai, Shandong Province, China, Bohai is engaged in the production, manufacturing and distribution of traditional Chinese herbal medicines, including capsules and other products, in China.

The company’s common stock will temporarily remain listed for quotation on the OTC Bulletin Board under the current symbol (LNKR) until new a symbol is assigned by Financial Industry Regulatory Authority, Inc. (FINRA).  The company will publicly announce the effective date of the symbol change.

“We are pleased to have completed our corporate name change to Bohai Pharmaceuticals Group, Inc. and believe that this new name properly reflects our primary business operations in China’s traditional Chinese medicine market,” stated Mr. Hongwei Qu, President and Chief Executive Officer of Bohai.  “We look forward to sharing future corporate developments with our shareholders.”

About Bohai Pharmaceuticals Group, Inc.

Based in the city of Yantai, Shandong Province, China, Bohai Pharmaceuticals Group, Inc. is engaged in the production, manufacturing and distribution of herbal pharmaceuticals based on traditional Chinese medicine in China.  Bohai’s medicines address common health problems such as rheumatism, rheumatoid arthritis, respiratory diseases, viral infections, gynecological diseases and cardio vascular issues.  Bohai’s products are sold either by prescription through hospitals or Over the Counter through local pharmacies and retail drug store chains.  Sales and distribution are managed and executed by about 260 sales representatives located in 20 offices throughout China as of November 2009.  Two of Bohai’s lead products, Tongbi Capsules and Tablets and Lung Nourishing Cream, are eligible for reimbursement under China’s National Medical Insurance Program.  In fiscal year ended June 30, 2009, these two products accounted for more than 50% of Bohai’s revenues.

Cautionary Note Regarding Forward Looking Statements

This press release and the statements of representatives of Bohai Pharmaceuticals Group, Inc. (the “Company”) related thereto contain, or may contain, among other things, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information.  These forward-looking statements are subject to significant involve known and unknown risks and uncertainties ad are often identified by the use of forward-looking terminology such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” or similar expressions.  Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect.  Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov).  All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors.  The Company undertakes no duty to update these forward-looking statements except as required by law.

Contact:

Trilogy Capital Partners - Asia

Darren Minton, Executive Vice President

Toll-free: 800-592-6067

info@trilogy-capital.com